The global cancer targeted therapy market is experiencing significant growth driven by advancements in genomic profiling and biomarker discovery, preference for precision medicine approaches, and robust pipeline of monoclonal antibodies and small molecule inhibitors. Cancer target therapy encompasses monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, gene therapy, and others. Targeted drugs inhibit the growth of cancer cells either by destroying them or slowing down their growth. Currently, targeted therapy is used in combination with traditional chemotherapy. It helps block the action of an abnormal protein (such as HER2) that promotes the growth of cancer cells.
The targeted therapy is divided into abemaciclib, ado-trastuzumab emtansine, Palbociclib, trastuzumab, and others. Trastuzumab (Herceptin) or lapatinib (TYKERB) can be prescribed to female patients whose breast tumors show an excessive amount of HER2 in lab tests. Kadcyla, Afinitor/Afinitor Disperz/Zortress, and Lynparza are a few of the crucial targeted therapeutic products. In August 2023, the Food and Drug Administration (FDA) approved trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer with a certain kind of mutation in the HER2 gene. It is regarded as the first targeted therapy for HER2-mutant lung cancer. Targeted therapy has gained notable traction in developed and emerging countries to treat cancer. With new product launches and the availability of an overwhelming number of medications, the targeted therapy segment is expected to hold a significant share of the cancer therapeutics market.
You can easily get a sample PDF of the report – https://www.businessmarketinsights.com/sample/BMIPUB00031706
Cancer Targeted Therapy Market Segmentation Analysis
Key segments that contributed to the derivation of the cancer targeted therapy market analysis are therapy type, indication, and distribution channel.
- By therapy type, the cancer targeted therapy market is segmented into monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, gene therapy, and others. The monoclonal antibodies segment dominated the market in 2024.
- In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024.
- By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.
Cancer Targeted Therapy Market Drivers and Opportunities:
Advancements in Genomic Profiling and Biomarker Discovery Driving Cancer Targeted Therapy Market
Emergence of genomic profiling and biomarker discovery are powerful agents of growth in the cancer targeted therapy marketplace, reshaping how cancer is diagnosed, stratified, and treated. Strides are being made to move away from the one-size-fits-all approach to cancer therapy to precision medicine approaches with detailed molecular information about the molecular drivers of individual tumors. Next-generation sequencing (NGS), whole exome sequencing, and liquid biopsies have allowed scientists and clinicians to discover many actionable genetic mutations (e.g., EGFR, ALK, KRAS, BRAF, HER2) that serve as targets for variable levels of specificity and other available or developing therapies.
These discoveries have opened systems of drug development for a new class of targeted drugs (e.g., tyrosine kinase inhibitors (TKIs), monoclonal antibodies, antibody-drug conjugates (ADCs)), that seek to inhibit cancer-drivers cascades without damaging healthy tissue, in theory decrease toxicity and improve overall efficacy. Clinical relevance of biomarkers has also expanded from simply supporting treatment selection; biomarkers can often be used to provide insight to disease progression (e.g. circulating tumor DNA (ctDNA), predicting development of therapeutic resistance, or guidance on eligibility for combination therapies. Furthermore, regulatory bodies, including the FDA and EMA, have provided increasing developmental guidance and approval for biomarker-driven therapeutics often through biosimilars. From the miniature stage-one trials discussed previously, tumor-agnostic indications have been developed where drug approval is related to treatment of patient populations based on predetermined genetic alterations rather than based solely on the cancer type.
Expanding Targeted Therapies into Rare Cancers and Tumors Driven by Specific Genetic Mutations
Expanding targeted therapies into rare cancers and tumors based on specific genetic alterations is a major and growing opportunity in the cancer targeted therapy space. The development of targeted therapies has historically taken place in high-prevalence cancers, like lung, breast, and colorectal cancers, where there are large patient populations that have well-characterized mutations, and where research and clinical trial expenses are justified. Advances in genomic sequencing and molecular diagnostics have uncovered actionable mutations in a whole host of less common and even ultra-rare tumor types, and have identified new therapeutic targets that may not have been known before.
Some tumors, like cholangiocarcinoma, gastrointestinal stromal tumors (GIST), anaplastic thyroid cancer, and certain sarcomas, to name a few, have well-characterized mutations—such as FGFR2 fusions, NTRK gene fusions, RET mutations, and KIT/PDGFRA alterations—that can be directly targeted. The development of tumor-agnostic therapies, like TRK inhibitors and checkpoint inhibitors approved for use in microsatellite instability-high (MSI-H) or TMB-high tumors, exemplifies that cancers can be treated based on their genetic profile, and not whereby tissue the cancer originated from. In fact, there are regulatory pathways in place to encourage these developments, which include accelerated pathways and orphan drug designations, incentivizing pharma companies to pursue therapies for smaller patient populations.
Cancer Targeted Therapy Market News and Key Development:
The cancer targeted therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the cancer targeted therapy market are:
- The FDA approved telisotuzumab vedotin (Emrelis) for adult patients with previously treated, locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) who have high c-Met protein overexpression. This antibody-drug conjugate (ADC) represents a targeted chemotherapy approach. (Source: AbbVie, Press Release, May 2025)
- Eli Lilly and Company announced that the US FDA approved an expanded indication for Verzenio (abemaciclib). High-risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following: tumors that of Grade 3). This expanded adjuvant indication removes the Ki-67 score requirement for patient selection. (Source: Eli Lilly and Company, Company Website, March 2023)
Get Premium Research Report at: https://www.businessmarketinsights.com/buy/BMIPUB00031706
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Contact us:
- If you have any questions about this report or would like further information, please contact us:
- Contact person: Ankit Mathur
- Email: sales@businessmarketinsights.com
- Phone: +16467917070
